Startseite Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Pharmacokinetic interactions of selective serotonin reuptake inhibitors with other commonly prescribed drugs in the era of pharmacogenomics

  • Vangelis G. Manolopoulos EMAIL logo , Georgia Ragia und Georgios Alevizopoulos
Veröffentlicht/Copyright: 29. Februar 2012
Veröffentlichen auch Sie bei De Gruyter Brill
Drug Metabolism and Personalized Therapy
Aus der Zeitschrift Band 27 Heft 1

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed to treat depression and a broad range of other comorbidities. The increased use of SSRIs in patients with various comorbidities treated with different drugs engenders the risk of pharmacokinetic drug interactions via cytochrome P450 (CYP450) enzymes inhibition. In the present review, we provide an overview of documented clinically significant drug interactions between SSRIs and other drugs co-prescribed in psychiatric patients for the same or other diseases. We further discuss the significance of drug interactions in the era of pharmacogenomics to underline the need for using information on both genotype and drug interactions towards implementing better clinical outcomes through personalized medicine.


Corresponding author: Dr. Vangelis G. Manolopoulos, Laboratory of Pharmacology, Medical School, Democritus University of Thrace, Dragana Campus, 68100 Alexandroupolis, Greece Phone/Fax: +30-2551-030523

Received: 2011-9-28
Accepted: 2012-1-23
Published Online: 2012-02-29
Published in Print: 2012-03-01

©2012 by Walter de Gruyter Berlin Boston

Heruntergeladen am 30.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/dmdi-2011-0033/html?lang=de
Button zum nach oben scrollen